ADAP Advocacy Opposes Inclusion of HIV Treatments in Medicare Drug Price Negotiations

TL;DR

ADAP Advocacy's push for an HIV medication carve-out in Medicare negotiations could safeguard vital treatments, ensuring PLWHA maintain access to life-saving drugs without compromise.

ADAP Advocacy has formally requested CMS to exclude HIV antiretroviral therapies from Medicare price negotiations, citing risks to treatment continuity and public health progress.

Exempting HIV medications from Medicare price negotiations could preserve the 'treatment as prevention' strategy, protecting PLWHA and preventing new infections for a healthier future.

ADAP Advocacy highlights the critical need to exempt HIV drugs from Medicare price talks to avoid jeopardizing decades of progress in HIV treatment and prevention.

Found this article helpful?

Share it with your network and spread the knowledge!

ADAP Advocacy Opposes Inclusion of HIV Treatments in Medicare Drug Price Negotiations

ADAP Advocacy has publicly opposed the inclusion of HIV antiretroviral therapies in the Medicare Drug Price Negotiation Program, raising concerns over the potential harm to individuals with HIV/AIDS. The organization's comments to the Centers for Medicare and Medicaid Services (CMS) argue for a carve-out to safeguard these critical medications. Brandon M. Macsata, CEO of ADAP Advocacy, pointed out the risks of restricting access to HIV treatments, including treatment discontinuation, higher mortality rates from opportunistic infections, and the emergence of drug-resistant HIV strains.

The advocacy is based on the 'treatment as prevention' approach, which is vital for improving health outcomes, curbing virus transmission, and lowering healthcare costs. ADAP Advocacy's detailed testimony to CMS underscores the importance of maintaining access to HIV medications during drug price negotiations. For more information on the proposed HIV carve-out and its public health impact, the full testimony is available.

blockchain registration record for this content

ADAP Advocacy Opposes Inclusion of HIV Treatments in Medicare Drug Price Negotiations

TL;DR

Found this article helpful?

Burstable Editorial Team